Member Info for Hurst10

White House blocks newFDA Covid 19 vaccine guide lines
“Median follow up duration of at least two months After completion of full vaccination regime “

Yes indeed, would be useful. Avacta's investor page

NY opening coming up, watch the price go 90 bid! + Stifel is around today.
Boris making his speech,and confirming what we know, that with the speed of the virus spreading, the demand for 5min tests being made available "en masse"is more than urgent.
Avct have manufacturing partners lined up and more to come.

FDA back again, putting the brakes on AZN's vaccine trials.
We will not see any approved vaccine from any major till Q2 next year earliest!!
Lots of safety issues, as adressed by the world's leading scientists.
Demand for Saliva based Antigen tests building up fast!!
https://www.reuters.com/article/us-health-coronavirus-vaccine-astrazenec-idUSKBN26L3TA

What you have to remember, we now have BAMS in clinical validation mode and the company have been talking and discussing commercial partnership post this event.
We have upcoming undisclosed milestone payments from existing JV’s , we have additional manufacturing capacity being announced with regards to the Covid test production and we have shortly confirmation of the first batch of test passing the approval, so the company can deliver to the professional market prior to the CE approval and suddenly market est. of the actual volume looks very real and the company’s Ebitda will be going up substantially.

The US buyers will love this

https://www.bruker.com/fileadmin/user_upload/8-PDF-Docs/Separations_MassSpectrometry/Literature/ApplicationNotes/1881181_MT-128_SARS-CoV-2_Antigen_Assay_ebook.pdf

I would take advantage of the current share price and buy more.
If you read the company presentation, you will see that the news flow going forward will accelerate both on the oncology side and off course with Covid 19 test and manufacturing news.
By the end of October, we will be in the new trading range 250-300.
Keep reading the RNS’ as they come out.

New research note from Finn Cap, with price target 310p with upside to 796.
Just assuming 10m tests a week 500m a year and a 30-40 % margin to Avacta at a price of ?5- ?10 per test, would imply EBITDA of ?750-2 bill. Per annum.

Professor Whitt statement at 11.00
Rapid testing supposed to be discussed
Stock being down this morning is as amazing as if France were to beat England at Lords

Market rumour before close, second lockdown in October " half term coming up ", We have Avacta on the 28th, just be patience and if you can pick up more before close, get some. US are buying, post market prints

This is an important strategic win for Falanx Cyber, offering validation at multiple levels. It is further customer and industry validation of Triarii MDR as an important cybersecurity offering for our customers and the flexibility of our new SentinelOne SOC service. It is also our first US-based MSP from the SolarWinds community to sign up to our services."
From the CEO.
What we should remember is that this only the beginning of their US expansion and once we have Solarwinds spinning off MSP, we will see further expansion on FLX's business in Europe and the States !

At the moment you also have US buyers and high profile shareholders such as Sequioa.Post the 28th, you will be saying:
" ghosh do you remember when you could buy Avacta at 176?
Rapid COVID saliva based antigen test will be the future.
Heathrow, Gatwick , the Government , Universities, hospitals, schools etc , the numbers will beyond any current estimates.
UK wants the economy back up running and rapid kit saliva kit test will be the future for years.
As I keep saying, we need to keep Avacta in the UK and not loose them to the US or Korea. Their oncology pipe line has JV's signed up for + a bill $ and phase 1 trials starting shortly.

Collection of saliva samples by patients themselves negates the need for direct interaction between health care workers and patients. This interaction is a source of major testing bottlenecks and presents a risk of nosocomial infection. Collection of saliva samples by patients themselves also alleviates demands for supplies of swabs and personal protective equipment. Given the growing need for testing, our findings provide support for the potential of saliva specimens in the diagnosis of SARS-CoV-2 infection.

No clinical test results as of yet.
Riding on AVACTA momentum !

Sorry, meant the 28th

What you all have to remember is Avacta is in closed period!
Cannot comment on all the various rumours.
Medusa this morning was a shamble with Avacta header.
The amount of self testing is still minimal.
The virus is spreading and helped by the flu now entering the scene.
Saliva based tests has proven to be more accurate than nasal swab.
The monthly test numbers will be very substantial and future revenue numbers beyond any current forecast.
The 24th will be quite something and being able to buy the stock below 200p is quite something.

I think you will find Medusa is the distributing agent when ready and nothing else

Newsflash- whole of the North East going into Lockdown

Agree, time everybody understands how big this will be.
US will sending over officials to ask for as much which is available .Avacta’s manufacturing partners will be going full steam. The market needs to prepare new analyst report as the numbers will be going north BIG TIME
Just stay long